Giredestrant

News

Roche's oral SERD flunks phase 3 breast cancer test

Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.

News

Roche delivers its data reveal for adjuvant giredestrant

Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?

News

Roche extols 'unprecedented' result with breast cancer drug

Roche's oral SERD giredestrant has achieved what the company says is a stellar result as adjuvant treatment for early breast cancer.

News

ESMO: Clear air emerges between Roche SERD and its rivals

Has Roche taken a lead in the oral SERD category of breast cancer therapies with data showing activity in wild-type ESR1 patients?

News

Roche's oral SERD comes good in 2nd-line breast cancer trial

Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

Roche's oral SERD flunks phase 3 breast cancer test

Roche delivers its data reveal for adjuvant giredestrant

Roche extols 'unprecedented' result with breast cancer drug

ESMO: Clear air emerges between Roche SERD and its rivals

Roche's oral SERD comes good in 2nd-line breast cancer trial

Data cues up AZ oral SERD filing in first-line breast cancer

After setback, Rhythm gets good news on Imcivree from FDA

Using AI-driven synthetic personas to take your insights fur...

Giredestrant

Editor's Picks